This article from the Wall Street Journal reports on Celgene's acquisition of Pharmion, which makes treatments for patients with blood cancer. Celgene, a biotech company, will make the purchase for $2.9 billion in cash and stock in an effort "to become a major global player in developing and marketing blood-cancer drugs," according to the article.